Breast Cancer Drugs In The Pipeline
 

Scientists in the clinic and the laboratory continue to work to drive breast cancer mortality rates down with breakthrough drugs. With tamoxifen's discovery 30 years behind us, and the impact of Herceptin still being felt, researchers are studying zoledronic acid, aromatase inhibitors and monoclonal antibodies, among others, with encouraging results. Data was presented at the CTRC-AACR San Antonio Breast Cancer Symposium.

More...